List of Intuniv drug patents
Intuniv is owned by Takeda Pharms Usa.
Intuniv contains Guanfacine Hydrochloride.
Intuniv has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Intuniv are:
- US6811794
- US6811794*PED
Intuniv was authorised for market use on 02 September, 2009.
Intuniv is available in tablet, extended release;oral dosage forms.
Intuniv can be used as treatment of attention-deficit hyperactivity disorder.
The generics of Intuniv are possible to be released after 04 January, 2023.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6811794 | TAKEDA PHARMS USA | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
Jul, 2022
(7 months ago) | |
|
US6811794
(Pediatric) | TAKEDA PHARMS USA | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
Jan, 2023
(a month ago) | |
Drugs and Companies using GUANFACINE HYDROCHLORIDE ingredient
Market Authorisation Date: 02 September, 2009
Treatment: Treatment of attention-deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic